Mulder S, Hammarstedt A, Nagaraj SB, Nair V, et al. A metabolomics based molecular pathway analysis for how the SGLT2-inhibitor
dapagliflozin may slow kidney function decline in patients with diabetes. Diabetes Obes Metab 2020 Mar 1. doi: 10.1111/dom.14018.
PMID: 32115853